Newer approaches to androgen deprivation therapy in prostate cancer

By Pitts W.R.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 882-882

Elsevier

Access to resources Recommend Favorite

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate

By Curran M.J.   Bihrle W.  

Urology, Vol. 53, Iss. 2, 1999-02 ,pp. : 423-424

Elsevier

Access to resources Recommend Favorite

Hormone-refractory Prostate Cancer? Anti-androgen Withdrawal and Intermittent Hormone Therapy

By Sciarra Alessandro   Casale Paolo   Colella Dario   Chiro Costantino Di   Silverio Franco Di  

Scandinavian Journal of Urology and Nephrology, Vol. 33, Iss. 4, 1999-09 ,pp. : 211-216

Informa Healthcare

Access to resources Recommend Favorite

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

By Brufsky A.   Fontaine-Rothe P.   Berlane K.   Rieker P.   Jiroutek M.   Kaplan I.   Kaufman D.   Kantoff P.  

Urology, Vol. 49, Iss. 6, 1997-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

By Wright G.L.   Grob M.   Haley C.   Grossman K.   Newhall K.   Petrylak D.   Troyer J.   Konchuba A.   Schellhammer P.F.   Moriarty R.  

Urology, Vol. 48, Iss. 2, 1996-08 ,pp. : 326-334

Elsevier

Access to resources Recommend Favorite